Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Acute Myocardial Infarction Market?
The market size for acute myocardial infarction has seen a robust increase in recent years. The growth is expected from $1.47 billion in 2024 to $1.56 billion in 2025 with a compound annual growth rate (CAGR) of 6.2%. The upward trend in the historical period can be linked to an increase in heart diseases associated with smoking, a growing incidence of hypertension, enhancements in emergency medical services, heightened consciousness about the risk factors of heart disease, and the early administration of aspirin in cardiovascular treatment.
What Growth Rate Is Forecasted for the Acute Myocardial Infarction Market by 2029?
The market size for acute myocardial infarction is predicted to experience significant growth in the coming years. The market is expected to increase to $1.97 billion in 2029, with a compound annual growth rate (CAGR) of 6.0%. Factors contributing to this growth during the projection period include the rising demand for minimally invasive heart procedures, increased investments in regenerative medicine for heart repair, an increasing occurrence of obesity and diabetes, and an intensified focus on personalized treatment for cardiac diseases. Key trends for the future include the use of artificial intelligence (AI) for early detection systems, wearable ECG monitors, nanotechnology for drug delivery, 3D bioprinting of heart tissues, and sophisticated robotic-assisted heart surgeries.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23291&type=smp
Which Key Companies Are Shaping the Future of the Acute Myocardial Infarction Market?
Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Ionis Pharmaceuticals Inc., CellProthera, Athersys Inc., BioCardia Inc., Serca Pharmaceuticals.
Which Factors Are Driving Demand in the Acute Myocardial Infarction Industry?
The acute myocardial infarction market is predicted to grow due to an increase in hypertension cases. This health concern, defined by constantly high blood pressure, escalates the probability of heart disease, stroke, and other medical complications. Increasing sedentary lifestyles due to desk-bound jobs, extended screen use, and insufficient exercise are leading to a rise in hypertension. This condition can lead to acute myocardial infarction as it harms arteries, aids plaque accumulation, and enhances the chances of blood clots obstructing coronary arteries. For example, a report by the Australian Bureau of Statistics in October 2024 stated that the hypertension rate in 2022 was at 11.6% (3.0 million people). Consequently, the surge in hypertension cases is fuelling the expansion of the acute myocardial infarction market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23291&type=smp
How Is the Acute Myocardial Infarction Market Segmented by Several Divisions?
The acute myocardial infarction market covered in this report is segmented –
1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI)
2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications
3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan
4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route
5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes
Subsegments:
1) ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
2) Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)
What are the Emerging Market Trends Driving the Growth of the Acute Myocardial Infarction Industry?
Leading enterprises in the field of acute myocardial infarction are centering their efforts on acquiring regulatory endorsements to broaden their product array, increase treatment effectiveness, and consolidate their standing in the market. These endorsements represent formal permissions from health bodies like the FDA and EMA, affirming the drugs and medical equipment’s safety, potency, and quality prior to being introduced in the market. For instance, Sungen Biomedical, a biopharmaceutical firm headquartered in China, in March 2025, received a Fast Track Designation from the FDA for SGC001, its monoclonal antibody drug. This drug, developed as the global first for emergency acute myocardial infarction (AMI) management, earned this designation due to its potential to decrease cardiomyocyte apoptosis and enhance blood movement in ischemic portions. Encouraged by promising preclinical results, which pointed towards improvements in recovery and lower mortality rates, the Fast Track status ensures quicker FDA interaction, speeding up the approval timeline and guaranteeing faster patient access to this groundbreaking AMI treatment.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report
Which Regions Are Driving Growth in the Acute Myocardial Infarction Market?
North America was the largest region in the acute myocardial infarction market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23291
This Report Delivers Insight On:
1. How big is the acute myocardial infarction market, and how is it changing globally?
2. Who are the major companies in the acute myocardial infarction market, and how are they performing?
3. What are the key opportunities and risks in the acute myocardial infarction market right now?
4. Which products or customer segments are growing the most in the acute myocardial infarction market?
5. What factors are helping or slowing down the growth of the acute myocardial infarction market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
